LUMEFANTRINE

Details

Stereochemistry	RACEMIC
Molecular Formula	C30H32Cl3NO
Molecular Weight	528.94
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCN(CCCC)CC(O)C1=CC(Cl)=CC2=C1C3=CC=C(Cl)C=C3\C2=C\C4=CC=C(Cl)C=C4

InChI

InChIKey=DYLGFOYVTXJFJP-MYYYXRDXSA-N

InChI=1S/C30H32Cl3NO/c1-3-5-13-34(14-6-4-2)19-29(35)28-18-23(33)17-27-25(15-20-7-9-21(31)10-8-20)26-16-22(32)11-12-24(26)30(27)28/h7-12,15-18,29,35H,3-6,13-14,19H2,1-2H3/b25-15-

HIDE SMILES / InChI

Molecular Formula	C30H32Cl3NO
Molecular Weight	528.94
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	1
Optical Activity	( + / - )

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022268s012lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.drugbank.ca/drugs/DB06708 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7866ec19-dfac-47d4-a53f-511a12643cbf

Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy (Coartem tablets). Lumefantrine is a blood schizonticide active against erythrocytic stages of Plasmodium falciparum. The exact mechanism by which lumefantrine exerts its antimalarial effect is unknown. The most common adverse reactions of Coartem in adults are headache, anorexia, dizziness, asthenia, arthralgia and myalgia.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Hemin 3 Target ID: Hemin Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022268s012lbl.pdf	Binding Agent 1076

Conditions

Condition	Modality	Targets	Highest Phase	Product
Malaria 96 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022268s012lbl.pdf	Curative		Approved 8583	COARTEM Approved Use Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see Clinical Studies (14.1) Launch Date 2009

C_max

Value	Dose	Co-administered	Analyte	Population
9.9 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20815879/	480 mg single, oral dose: 480 mg route of administration: Oral experiment type: SINGLE co-administered: ARTEMETHER	ARTEMETHER	LUMEFANTRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10681341/	480 mg 1 times / day multiple, oral dose: 480 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LUMEFANTRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
279 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20815879/	480 mg single, oral dose: 480 mg route of administration: Oral experiment type: SINGLE co-administered: ARTEMETHER	ARTEMETHER	LUMEFANTRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
356 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10681341/	480 mg 1 times / day multiple, oral dose: 480 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LUMEFANTRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
118 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/20815879/	480 mg single, oral dose: 480 mg route of administration: Oral experiment type: SINGLE co-administered: ARTEMETHER	ARTEMETHER	LUMEFANTRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED
6.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10681341/	480 mg 1 times / day multiple, oral dose: 480 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LUMEFANTRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
0.3% OTHER GOV'T https://www.tmda.go.tz/uploads/1658391574-T16H0686SmPCV1.pdf	unknown, unknown		LUMEFANTRINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
0.3% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/10681341/	480 mg 1 times / day multiple, oral dose: 480 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LUMEFANTRINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
240 mg 3 times / day multiple, oral Recommended Dose: 240 mg, 3 times / day Route: oral Route: multiple Dose: 240 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 2 Health Status: unhealthy Age Group: 2 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	Disc. AE: Urticaria... AEs leading to discontinuation/dose reduction: Urticaria (grade 3-4) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
480 mg 3 times / day multiple, oral Recommended Dose: 480 mg, 3 times / day Route: oral Route: multiple Dose: 480 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 25 Health Status: unhealthy Age Group: 25 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	Disc. AE: Abdominal pain... Other AEs: Dyspnea, Pulmonary edema... AEs leading to discontinuation/dose reduction: Abdominal pain (grade 1-2, uncommon) Other AEs: Dyspnea (grade 3-4, uncommon) Pulmonary edema (grade 3-4, uncommon) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
240 mg 3 times / day multiple, oral Recommended Dose: 240 mg, 3 times / day Route: oral Route: multiple Dose: 240 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 3 Health Status: unhealthy Age Group: 3 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	Disc. AE: Vomiting, Urticaria... AEs leading to discontinuation/dose reduction: Vomiting (grade 3-4, most common) Urticaria (grade 3-4) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf

AEs

AE	Significance	Dose	Population
Urticaria	grade 3-4 Disc. AE	240 mg 3 times / day multiple, oral Recommended Dose: 240 mg, 3 times / day Route: oral Route: multiple Dose: 240 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 2 Health Status: unhealthy Age Group: 2 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Abdominal pain	grade 1-2, uncommon Disc. AE	480 mg 3 times / day multiple, oral Recommended Dose: 480 mg, 3 times / day Route: oral Route: multiple Dose: 480 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 25 Health Status: unhealthy Age Group: 25 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Dyspnea	grade 3-4, uncommon	480 mg 3 times / day multiple, oral Recommended Dose: 480 mg, 3 times / day Route: oral Route: multiple Dose: 480 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 25 Health Status: unhealthy Age Group: 25 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Pulmonary edema	grade 3-4, uncommon	480 mg 3 times / day multiple, oral Recommended Dose: 480 mg, 3 times / day Route: oral Route: multiple Dose: 480 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 25 Health Status: unhealthy Age Group: 25 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Vomiting	grade 3-4, most common Disc. AE	240 mg 3 times / day multiple, oral Recommended Dose: 240 mg, 3 times / day Route: oral Route: multiple Dose: 240 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 3 Health Status: unhealthy Age Group: 3 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf
Urticaria	grade 3-4 Disc. AE	240 mg 3 times / day multiple, oral Recommended Dose: 240 mg, 3 times / day Route: oral Route: multiple Dose: 240 mg, 3 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf	unhealthy, 3 Health Status: unhealthy Age Group: 3 Sex: M+F Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_MedR_P2.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438 inducer 440	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2C19 2057 CYP2E1 1060 CYP3A4/5 296 CYP4A9/11 35		CYP1A2 832 CYP2B6 669 CYP2C8 198 CYP2C19 329 CYP3A 142 CYP1A1 151

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP4A9/11 35	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 30, (PMDA_I100_1 in Japanese) 38	no [IC50 >2.0 uM]
CYP1A1 272	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 250	no
CYP1A2 2333	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 38, 250	no
CYP2B6 1160	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 38, 250	no
CYP2C19 2141	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 38, 250	no
CYP2C8 1117	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 38, 250	no
CYP2C9 2497	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 38, 250	no
CYP3A 317	inducer 1966 Sources: https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=250 Page: (PMDA_I100_1 in Japanese) 38, 250	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=11, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=30, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_I100_1.pdf#page=249 Page: (ClinPharm) 2, 11, 30, (PMDA_I100_1 in Japanese) 38, 248-249	yes [IC50 0.997 uM]

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=9, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_K100_1.pdf#page=61 Page: (ClinPharm) 7, 9, 11, 21, (PMDA_K100_1 in Japanese) 61	major		yes (co-administration study) Comment: Human liver microsomes, Recombinant CYP3A4; Modest changes (<2.5-fold increase) in systemic exposure were observed with inhibitors or substrates of CYP3A4 including ketoconazole, mefloquine or quinine. The concentrations seen in the ketoconazole drug interaction study were within the range of systemic concentrations of Coartem seen in malaria patients in Phase III efficacy and safety studies. The concurrent oral administration of ketoconazole (400 mg on Day 1 followed by 200 mg on days 2,3, 4 and 5) with co-artemether (single dose of 4 tablets of 20 mg artemether/120 mg lumefantrine) led to a modest increase in lumefantrine (1.3-fold (Cmax), 1.6-fold (AUClast)) exposure in healthy subjects. Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=9, https://www.pmda.go.jp/drugs/2016/P20161222001/300242000_22800AMX00727_K100_1.pdf#page=61 Page: (ClinPharm) 7, 9, 11, 21, (PMDA_K100_1 in Japanese) 61

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_PharmR.pdf#page=77, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_ClinPharmR.pdf#page=16 Page: 77, (ClinPharm) 16
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022268s000_PharmR.pdf#page=77 Page: 77.0		DESBUYL-BENFLUMETOL 3

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-6299	http://www.3bsc.com/index/pro_info.php?id=116861
AA Blocks	AA0036I3	https://www.aablocks.com/goods/Goods/detail?id=AA0036I3
Aaron Chemicals	AR00379V	http://www.aaronchem.com/82186-77-4
abcr GmbH	AB436173	http://www.abcr.com/shop/en/AB436173
Achemo Scientific Limited	AC-74186	http://www.achemo.com/search/?Keyword= 82186-77-4
Achemtek	0104-019643	http://www.achemtek.com/82186-77-4
Acorn PharmaTech	ACN-048710	http://www.acornpharmatech.com/
AK Scientific, Inc. (AKSCI)	65683	http://www.aksci.com/item_detail.php?cat=65683
Alfa Chemistry	AP82186774	https://reagents.alfa-chemistry.com/product/lumefantrine-cas-82186-77-4-16977.html
Alsachim	1354	http://www.alsachim.com/product-C1742-glo.bal-view.html
AstaTech, Inc.	24538	http://www.astatechinc.com/CPSResult.php?CRNO=27834
Aurum Pharmatech LLC	S-4170	http://www.Aurumpharmatech.com/Product/ProductDetails/S_4170
AvaChem Scientific	2433	http://www.avachem.com/productSearch.asp?2433
Avantor Inc	TCL0256-25G	https://us.vwr.com/store/product/16813025/lumefantrine-98-0-by-hplc-titration-analysis
Avantor Inc	TCL0256-5G	https://us.vwr.com/store/product/16813025/lumefantrine-98-0-by-hplc-titration-analysis
BLD Pharm	BD115323	http://www.bldpharm.com/products/82186-77-4.html
BLD Pharm	BD220185	http://www.bldpharm.com/products/204133-10-8.html
Boerchem	BC682501	http://www.boerchem.com/?product_40130.html
Chem Scene	CS-5130	http://www.chemscene.com/82186-77-4.html
Chemenu	CM110477	http://www.chemenu.com/products/CM110477
ChemMol	30110287	http://www.chemmol.com/chemmol/30110287.html
ChemMol	44011083	http://www.chemmol.com/chemmol/44011083.html
ChemMol	49400258	http://www.chemmol.com/chemmol/49400258.html
ChemMol	99172515	http://www.chemmol.com/chemmol/99172515.html
Chemspace	CSSB00016988937	https://chem-space.com/CSSB00016988937
CSNpharm	CSN10394	https://www.csnpharm.com/products/lumefantrine.html
eNovation Chemicals	D506030	https://www.enovationchem.com/ProductDetails.asp?ProductID=D506030
eNovation Chemicals	D674512	https://www.enovationchem.com/ProductDetails.asp?ProductID=D674512
eNovation Chemicals	D767145	https://www.enovationchem.com/ProductDetails.asp?ProductID=D767145
Glentham Life Sciences	GP5101	http://www.glentham.com/products/product/GP5101/
Hairui	HR126098	http://www.hairuichem.com/en/product/82186-77-4.html
Lab Network	LN00175760	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00175760
Matrix Scientific	76072	https://www.matrixscientific.com/076072.html
MedChem Express	HY-B0803	https://www.medchemexpress.com/Lumefantrine.html
MuseChem	I004976	https://www.musechem.com/product/I004976.html
Oakwood	79421	http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=64595&ExtHyperLink=1
OChem	10386	http://www.ocheminc.com/index.php?act=psearch&pid=186L774
Parchem	29326	http://www.parchem.com/chemical-supplier-distributor/Lumefantrine-019326.aspx
Renno Tech	RL05134	http://www.rennotech.com/product_show.asp?id=5383
Selleck Chemicals	S3746	http://www.selleckchem.com/products/lumefantrine.html
Sigma-Aldrich	1370746_USP	https://www.sigmaaldrich.com/catalog/product/usp/1370746?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	L5420_SIGMA	https://www.sigmaaldrich.com/catalog/product/sigma/l5420?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule	S533785	http://www.smolecule.com/products/s533785
Smolecule	S533786	http://www.smolecule.com/products/s533786
TCI (Tokyo Chemical Industry)	L0256	http://www.tcichemicals.com/eshop/en/us/commodity/L0256/index.html
THE BioTek	bt-274421	https://www.thebiotek.com/product/inhibitors/bt-274421
THE BioTek	bt-274423	https://www.thebiotek.com/product/inhibitors/bt-274423
VladaChem	VL279049-25G	https://www.vladachem.com/product.php?products=82186-77-4
Yuhao Chemical	SY0308	http://www.chemyuhao.com/82186-77-4.html

PubMed

Title	Date	PubMed
In vitro and in vivo combination of cepharanthine with anti-malarial drugs.	2014-03-12	24618129
Breakdown of phosphatidylserine asymmetry following treatment of erythrocytes with lumefantrine.	2014-02-20	24561477
A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.	2013-12-17	24341604
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.	2013-07	23612203
Synthesis and antimalarial efficacy of two-carbon-linked, artemisinin-derived trioxane dimers in combination with known antimalarial drugs.	2013-03-28	23425037
In vitro activity of antiretroviral drugs against Plasmodium falciparum.	2011-11	21876053
Synthesis of novel 6-phenyl-2,4-disubstituted pyrimidine-5-carbonitriles as potential antimicrobial agents.	2011-09	21849221
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.	2010-03	20065051
Antimalarial drugs: QT prolongation and cardiac arrhythmias.	2005-05	15934850

Patents

Sample Use Guides

In Vivo Use Guide

Tablets should be administered over 3 days for a total of 6 doses: an initial dose, second dose after 8 hours and then twice-daily (morning and evening) for the following 2 days. The adult dosage for patients with bodyweight of 35 kg and above is 4 tablets per dose for a total of 6 doses. Tablets are scored and contain 20 mg rtemether and 120 mg lumefantrine.

Route of Administration: Oral

In Vitro Use Guide

IC90 is higher in Plasmodium falciparum strain T-996 compared with strain LS-21: for Lumefantrine 293.03 and 95.61 nmol/L (154.69 and 50.47 ng/ml of EMM).

Substance Class	Chemical Created by `admin` on `Wed Apr 02 07:52:42 GMT 2025` Edited by `admin` on `Wed Apr 02 07:52:42 GMT 2025`
Record UNII	F38R0JR742
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

COARTEM COMPONENT LUMEFANTRINE

Preferred Name

English

LUMEFANTRINE

Official Name

English

LUMEFANTRINE [VANDF]

Common Name

English

DL-BENFLUMELOL

Common Name

English

LUMEFANTRINE [HSDB]

Common Name

English

BENFLUMELOL

Common Name

English

LUMEFANTRINUM [WHO-IP LATIN]

Common Name

English

lumefantrine [INN]

Common Name

English

GNF-PF-1971

Code

English

LUMEFANTRINE [MART.]

Common Name

English

9H-FLUORENE-4-METHANOL, 2,7-DICHLORO-9-((4-CHLOROPHENYL)METHYLENE)-.ALPHA.-((DIBUTYLAMINO)METHYL)-, (Z)-

Systematic Name

English

LUMEFANTRINE [JAN]

Common Name

English

LUMEFANTRINE [USP MONOGRAPH]

Common Name

English

BENFLUMETOL

Common Name

English

LUMEFANTRINE [MI]

Common Name

English

LUMEFANTRINE [USAN]

Common Name

English

(±)-2,7-DICHLORO-9-((Z)-P-CHLOROBENZYLIDENE)-.ALPHA.((DIBUTYLAMINO)METHYL)FLUORENE-4-METHANOL

Common Name

English

CPG-56695

Code

English

LUMEFANTRINE [USP-RS]

Common Name

English

2-DIBUTYLAMINO-1-(2,7-DICHLORO-9-(1-(4-CHLOROPHENYL)METH-(Z)-YLIDENE)-9H-FLUOREN-4-YL)ETHANOL

Common Name

English

Lumefantrine [WHO-DD]

Common Name

English

LUMEFANTRINE [ORANGE BOOK]

Common Name

English

LUMEFANTRINE [WHO-IP]

Common Name

English

Classification Tree Code System Code

LIVERTOX

577